CellPoint gets FDA OK for Phase III trial of SPECT agent EC-G

04/25/2012 | Denver Post, The

CellPoint Chief Financial Officer Terry Colip said the company is aiming for commercialization of its SPECT agent EC-G in 2013. In March, the company received FDA approval for a Phase III lung cancer trial. The agent is in a Phase II clinical study involving patients with coronary artery disease. CellPoint officials say the agent will offer a lower-cost diagnostic technique.

View Full Article in:

Denver Post, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ